GCT is a rare tumour that affects the synovium and tendon sheaths. More: Turalio becomes first FDA-approved treatment for tenosynovial giant cell tumour Source: News
read moreThe decision comes from positive cardiovascular outcomes and renal data from the Phase III DECLARE-TIMI 58 trial. More: AZ’ Forxiga label updated in EU for type II diabetes Source: News
read moreThe collaboration will combine Sosei’s structure-based drug design capabilities with Takeda’s discovery, development and therapeutic area expertise. More: Sosei Heptares, Takeda embark on strategic R&D partnership Source: News
read moreThe 20 hospitals set to be upgraded at a cost of £850 million have been announced. More: New PM pledges £1.8bn to NHS Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals